It has a collaboration agreement with Par Pharmaceutical for the distribution and marketing of the company's generic formulation of Abbott's Biaxin XL ...
It has a collaboration agreement with Par Pharmaceutical for the distribution and marketing of the company's generic formulation of Abbott's Biaxin XL ...
It has a collaboration agreement with Par Pharmaceutical for the distribution and marketing of the company's generic formulation of Abbott's Biaxin XL ...
Biaxin XL and generic versions have total annual US sales of about $200 million, Watson said. (Reporting by Lewis Krauskopf, editing by Gerald E. McCormick)
The company noted that its Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin XL, which is designed for the treatment of ...
Watson Pharmaceuticals Inc. (WPI) has launched a generic version of Abbott Laboratories' (ABT) Biaxin XL, used to treat or prevent infections that may be ...
According to IMS Health data, Biaxin XL and its generic equivalents had total US sales of nearly $200 million for the 12-months ending September 2007. ...
Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent infections that ...
The company's new 500-mg Clarithromycin Extended-Release tablets are a generic version of Abbott Laboratories (NYSE:ABT) ' Biaxin XL. Biaxin XL and generic ...